| Document |
Document Title |
|
WO/2012/098235A1 |
The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
|
|
WO/2012/089644A1 |
A process for preparing 3-alkylsulfinylbenzoyl derivatives of the formula (IIIa) by reaction of 3-alkylsulfinylbenzoic acids of the formula (Ib) with compounds of the formula (II) in the presence of a chlorinating agent and a base is des...
|
|
WO/2012/085474A1 |
The present invention relates to a process for preparing chiral amino acids with excellent enantiomeric excesses.
|
|
WO/2012/087182A2 |
The invention relates to novel substituted methyl amines, serotonin 5-HT6 receptor antagonists, active ingredients, pharmaceutical compositions and a method for preventing and treating diseases of the central nervous system, as well as t...
|
|
WO/2012/082551A2 |
Described herein is a composition according to formula I or its precursor, formula II: CX1X3=CX2-(R1)p-CZ1 Z2-SO2M (I) wherein X1, X2, and X3 are independently selected from H, F, Cl, Br, I, CF3 and CH3, and wherein at least one of X1, X...
|
|
WO/2012/081488A1 |
[Problem] To provide an acid catalyst which can reduce the quantity of waste in an organic synthesis reaction and which does not corrode a reactor and is nontoxic. [Solution] The problem is resolved by using a bis(trifluoromethanesulfony...
|
|
WO/2012/072489A1 |
The invention relates to novel alpha,beta-unsaturated imines, to a method for producing same, to the use thereof for combating animal pests, including anthropods and in particular insects, and to the use thereof in vector control.
|
|
WO/2012/069421A1 |
Compounds of general formula (I) their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroid...
|
|
WO/2012/061926A1 |
The invention relates to bisarylsulfone and dialkylarylsulfone compounds (e.g., compounds according to any of Formulas (I)-(IX) or compounds (1)-(227) of Tables 4 and 5) useful in treating conditions associated with calcium channel funct...
|
|
WO/2012/055034A1 |
Compounds of Formula I are disclosed: wherein L, A, R1, R2, R3A, R3B, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be...
|
|
WO/2012/054526A2 |
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...
|
|
WO/2012/054521A2 |
The present application describes compounds of Formula I and Formula IA and as disclosed herein, that are useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.
|
|
WO/2012/046771A1 |
The inventors have intensively studied on compounds that have Aβ42 production inhibitory activity and have found that a compound (I) of the present invention, wherein a carboxylic acid or a tetrazole group is bonded to a cycloalkane moi...
|
|
WO/2012/042532A1 |
Processes for the preparation of N-[4-cyano-3-(trifluoro methyl) phenyl]-3-[(4-fluorophenyl) sulphonyl]-2-hydroxy-2- methyl propanamide or Bicalutamide are provided. A method for purifying the Bicalutamide using ethyl acetate solvent res...
|
|
WO/2012/034472A1 |
Cyano benzenedicarboxamide compounds of formula (I), preparing methods and as agricultural insecticides uses thereof. The compounds have broad-spectrum insecticidal activities.
|
|
WO/2012/036257A1 |
Provided is a composition for maintaining platelet function that has as the active ingredient a compound represented by general formula (I) [in the formula: X indicates a phenylene group; Y indicates a hydrogen atom or -(CH2)mR1; m indic...
|
|
WO/2012/032534A2 |
The present invention relates to Furanose derivatives and their applications in synthesis of statins.
|
|
WO/2012/033225A1 |
The present invention relates to a novel method for producing a pyridazinone compound and an intermediate thereof as shown in the following scheme: wherein the symbols are as defined in the specification.
|
|
WO/2012/026813A2 |
The invention relates to novel therapeutic compounds, more in particular to biologically active analogs of geranylgeranylacetone (GGA), and various use thereof. Provided is a compound of the general formula (II) and uses thereof as medic...
|
|
WO/2012/020483A1 |
A 3-aminooxalyl aminobenzamide derivative used in an insecticide and miticide is provided. The 3-aminooxalyl aminobenzamide derivative is represented by the following formula. (In the formula, R1 represents a C1 to C3 halo alkylthio grou...
|
|
WO/2012/016779A1 |
Sulphur-containing and sulphone-containing aromatic perfluoroalkane monomer that can be used for the manufacture of a polymer membrane intended for a fuel cell of PEM type, said functionalized monomer corresponding to the formula (I): E1...
|
|
WO/2012/010575A1 |
The invention relates to (4-halogenalkyl-3-thiobenzoyl)cyclohexanediones of general formula (I) and to the use thereof as herbicides. In said formula (I), X, Y, R1, R2, R3 and R4 represent radicals such as hydrogen and organic radicals s...
|
|
WO/2012/010574A1 |
The invention relates to (4-trifluormethyl-3-thiobenzoyl)cyclohexanediones of general formula (I) and use thereof as herbicides. In said formula (I) X, R1, R2, R3 and R4 represent radicals such as hydrogen and organic radicals such as al...
|
|
WO/2012/010644A1 |
Process for the synthesis of an isothiocyanate of general formula (I) SCN‑R1-R4-R2 in which R1 and R2 represent, independently of one another, an alkyl, aryl or alkylaryl group, R4 represents a carbonyl, sulphinyl or sulphonyl group or...
|
|
WO/2012/011125A1 |
The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for thei...
|
|
WO/2012/007644A1 |
The invention relates to novel arylamide derivatives having formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, where R1 - R11, R', R", z and X are as defined in the claims. The arylamide derivatives of formula (...
|
|
WO/2012/008435A1 |
Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represente...
|
|
WO/2012/005229A1 |
Disclosed is a compound which is represented by general formula (I) and has an inhibitory effect on ADAM17, a salt thereof, or a solvate thereof. In formula (I), X represents a phenylene group, Y represents a hydrogen atom, -(CH2)mR1, or...
|
|
WO/2012/004443A1 |
The invention relates to compounds which are active pharmaceutical principles used for treating and/or preventing inflammation and/or cancer, having formula (I) in which -X- is a single bond, -NH- or -CO-, and -Ar is an aromatic radical ...
|
|
WO/2011/161101A1 |
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for t...
|
|
WO/2011/158918A1 |
Disclosed is a novel polynuclear metal compound which is specific, has high catalytic properties, and has great potential as a novel functional material or the like. Specifically disclosed is a polynuclear metal compound which has at lea...
|
|
WO/2011/154677A1 |
The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
|
|
WO/2011/131542A1 |
The invention relates to a method for producing products, characterized in that (A) at least one compound of general formula (I), where R1 is selected from hydrogen and C1-C4-alkyl, and a sulfonating agent are reacted with one another at...
|
|
WO/2011/132171A1 |
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups ...
|
|
WO/2011/131665A1 |
The invention relates to a method for producing 4,4'-dichlorodiphenyl sulfone from monochlorobenzene in which the maximum concentration of hydrocarbons containing 5 to 8 carbon atoms is 100 ppm relative to the total weight of the monochl...
|
|
WO/2011/131508A1 |
The invention relates to a method for producing 4,4'-dichlorodiphenyl sulfone, comprising the reaction of monochlorobenzene with liquid sulfur trioxide that has a maximum boron concentration of 100 ppm relative to the total weight of the...
|
|
WO/2011/129967A2 |
The description includes materials that may be useful for fuel cell applications such as in the manufacture of fuel cell electrodes, proton exchange membranes (PEM), as catalyst additives or in tie layers designed to be thermally and che...
|
|
WO/2011/126099A1 |
A medication that has excellent agonist effects on CaSR and enables the prevention or treatment of diabetes or obesity is provided by means of compound represented by formula (I) defined in the description, or a composition comprising a ...
|
|
WO/2011/107465A1 |
The invention relates to a method for producing 4-chlorobenzene sulphonic acid from 2-chlorobenzene sulphonic acid and/or 3-chlorobenzene sulphonic acid, comprising the reaction of 2-chlorobenzene sulphonic acid and/or 3-chlorobenzene su...
|
|
WO/2011/101321A1 |
A description is given of 3-aminocarbonyl-substituted benzoylcyclohexanediones of the general formula (I) as herbicides. In this formula (I), R1 to R5 stand for radicals such as hydrogen, organic radicals such as alkyl, and other radic...
|
|
WO/2011/102514A1 |
A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a prodrug of the compound or the salt, which has an excellent inhibitory activity on long chain fatty acids family member 6 ...
|
|
WO/2011/098985A1 |
The invention relates to compounds of formula (Formula III) (III) and of formula (Formula (IV) (IV), to methods for producing said compounds, and to the use thereof in the synthesis of saxagliptin.
|
|
WO/2011/099572A1 |
Provided is a fluoroalkane derivative represented by general formula (1): R-SO2-Ar-O-R1 (1) wherein Ar represents a substituted or unsubstituted divalent aromatic group having 8-30 nuclear atoms; R1 represents a saturated or unsaturated ...
|
|
WO/2011/093423A1 |
Disclosed is a method for producing a compound represented by formula (E)-I characterized by comprising precipitating crystals of the compound represented by formula (E)-I in the coexistence of an acid and shifting the equilibrium of the...
|
|
WO/2011/088209A2 |
This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and...
|
|
WO/2011/088015A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2011/073143A1 |
Substituted cyanobutyrates of the formula I in which the variables are defined according to the description, processes and intermediates for preparing the compounds of the formula I and their N-oxides, their agriculturally suitable salts...
|
|
WO/2011/073473A1 |
Vinyl sulphone functionalised lipid systems. Synthesis and uses. Compound comprising a molecule of lipid nature and a vinyl sulphone group permitting the realisation of lipidation of biomolecules in a highly efficacious and simple manner...
|
|
WO/2011/058918A1 |
Disclosed is a compound represented by formula (I) [wherein Ra and Rb independently represent an organic group which has 1 to 30 carbon atoms and may have a substituent; X1 and X2 independently represent a hydrogen atom, a halogen atom, ...
|
|
WO/2011/059042A1 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...
|
